Safety	0	6	O
of	7	9	O
verteporfin	10	21	B-Drug_or_compound
for	22	25	O
treatment	26	35	O
of	36	38	O
subfoveal	39	48	B-Multi-tissue_structure
choroidal	49	58	I-Multi-tissue_structure
neovascular	59	70	I-Multi-tissue_structure
membranes	71	80	I-Multi-tissue_structure
associated	81	91	O
with	92	96	O
age	97	100	O
-	100	101	O
related	101	108	O
macular	109	116	B-Tissue
degeneration	117	129	O
.	129	130	O

Photodynamic	132	144	O
therapy	145	152	O
(	153	154	O
PDT	154	157	O
)	157	158	O
is	159	161	O
a	162	163	O
novel	164	169	O
treatment	170	179	O
entity	180	186	O
that	187	191	O
exploits	192	200	O
the	201	204	O
photophysical	205	218	O
properties	219	229	O
of	230	232	O
various	233	240	O
photosensitive	241	255	O
chemical	256	264	O
entities	265	273	O
which	274	279	O
,	279	280	O
upon	281	285	O
light	286	291	O
activation	292	302	O
,	302	303	O
results	304	311	O
in	312	314	O
targeted	315	323	O
photooxidation	324	338	O
and	339	342	O
subsequent	343	353	O
tissue	354	360	B-Tissue
destruction	361	372	O
.	372	373	O

The	374	377	O
antiangiogenic	378	392	O
properties	393	403	O
of	404	406	O
PDT	407	410	O
have	411	415	O
been	416	420	O
adapted	421	428	O
for	429	432	O
treatment	433	442	O
of	443	445	O
subfoveal	446	455	B-Multi-tissue_structure
choroidal	456	465	I-Multi-tissue_structure
neovascular	466	477	I-Multi-tissue_structure
membranes	478	487	I-Multi-tissue_structure
due	488	491	O
to	492	494	O
disease	495	502	O
states	503	509	O
such	510	514	O
as	515	517	O
age	518	521	O
-	521	522	O
related	522	529	O
macular	530	537	B-Tissue
degeneration	538	550	O
(	551	552	O
AMD	552	555	O
)	555	556	O
.	556	557	O

Historically	558	570	O
,	570	571	O
PDT	572	575	O
has	576	579	O
been	580	584	O
limited	585	592	O
by	593	595	O
a	596	597	O
lack	598	602	O
of	603	605	O
suitable	606	614	O
photosensitive	615	629	O
dyes	630	634	O
.	634	635	O

However	636	643	O
,	643	644	O
agents	645	651	O
such	652	656	O
as	657	659	O
verteporfin	660	671	B-Drug_or_compound
,	671	672	O
a	673	674	O
second	675	681	O
-	681	682	O
generation	682	692	O
benzoporphyrin	693	707	B-Drug_or_compound
derivative	708	718	O
,	718	719	O
appear	720	726	O
to	727	729	O
be	730	732	O
free	733	737	O
from	738	742	O
the	743	746	O
extensive	747	756	O
phototoxicity	757	770	O
that	771	775	O
limited	776	783	O
the	784	787	O
success	788	795	O
of	796	798	O
previous	799	807	O
agents	808	814	O
.	814	815	O

Verteporfin	816	827	B-Drug_or_compound
has	828	831	O
a	832	833	O
high	834	838	O
affinity	839	847	O
for	848	851	O
choroidal	852	861	B-Multi-tissue_structure
neovascular	862	873	I-Multi-tissue_structure
membranes	874	883	I-Multi-tissue_structure
,	883	884	O
typically	885	894	O
found	895	900	O
with	901	905	O
exudative	906	915	O
AMD	916	919	O
,	919	920	O
and	921	924	O
upon	925	929	O
photoactivation	930	945	O
results	946	953	O
in	954	956	O
targeted	957	965	O
microvascular	966	979	B-Tissue
damage	980	986	O
and	987	990	O
thrombus	991	999	B-Pathological_formation
formation	1000	1009	O
with	1010	1014	O
resultant	1015	1024	O
vessel	1025	1031	B-Multi-tissue_structure
occlusion	1032	1041	O
.	1041	1042	O

Scrutiny	1043	1051	O
of	1052	1054	O
diagnostic	1055	1065	O
indicators	1066	1076	O
for	1077	1080	O
verteporfin	1081	1092	B-Drug_or_compound
administration	1093	1107	O
,	1107	1108	O
including	1109	1118	O
critical	1119	1127	O
angiographic	1128	1140	O
evaluation	1141	1151	O
of	1152	1154	O
lesion	1155	1161	B-Pathological_formation
size	1162	1166	O
and	1167	1170	O
visual	1171	1177	O
acuity	1178	1184	O
,	1184	1185	O
is	1186	1188	O
essential	1189	1198	O
to	1199	1201	O
treatment	1202	1211	O
success	1212	1219	O
.	1219	1220	O

Large	1221	1226	O
lesions	1227	1234	B-Pathological_formation
with	1235	1239	O
relatively	1240	1250	O
good	1251	1255	O
visual	1256	1262	O
acuity	1263	1269	O
(	1270	1271	O
20	1271	1273	O
/	1273	1274	O
50	1274	1276	O
or	1277	1279	O
better	1280	1286	O
)	1286	1287	O
may	1288	1291	O
be	1292	1294	O
at	1295	1297	O
particular	1298	1308	O
risk	1309	1313	O
for	1314	1317	O
marked	1318	1324	O
vision	1325	1331	O
loss	1332	1336	O
following	1337	1346	O
verteporfin	1347	1358	B-Drug_or_compound
administration	1359	1373	O
.	1373	1374	O

Lesion	1375	1381	B-Pathological_formation
composition	1382	1393	O
also	1394	1398	O
appears	1399	1406	O
to	1407	1409	O
influence	1410	1419	O
visual	1420	1426	O
outcome	1427	1434	O
with	1435	1439	O
verteporfin	1440	1451	B-Drug_or_compound
use	1452	1455	O
.	1455	1456	O

The	1457	1460	O
safety	1461	1467	O
of	1468	1470	O
verteporfin	1471	1482	B-Drug_or_compound
is	1483	1485	O
directly	1486	1494	O
dependent	1495	1504	O
upon	1505	1509	O
the	1510	1513	O
appropriate	1514	1525	O
integration	1526	1537	O
of	1538	1540	O
dosage	1541	1547	O
,	1547	1548	O
infusion	1549	1557	O
and	1558	1561	O
light	1562	1567	O
activation	1568	1578	O
required	1579	1587	O
for	1588	1591	O
a	1592	1593	O
suitable	1594	1602	O
pharmacotherapeutic	1603	1622	O
outcome	1623	1630	O
.	1630	1631	O

When	1632	1636	O
used	1637	1641	O
appropriately	1642	1655	O
,	1655	1656	O
and	1657	1660	O
with	1661	1665	O
adequate	1666	1674	O
patient	1675	1682	B-Organism
education	1683	1692	O
regarding	1693	1702	O
photosensitivity	1703	1719	O
,	1719	1720	O
the	1721	1724	O
risk	1725	1729	O
-	1729	1730	O
benefit	1730	1737	O
of	1738	1740	O
verteporfin	1741	1752	B-Drug_or_compound
for	1753	1756	O
the	1757	1760	O
medical	1761	1768	O
treatment	1769	1778	O
of	1779	1781	O
neovascular	1782	1793	O
AMD	1794	1797	O
is	1798	1800	O
favourable	1801	1811	O
.	1811	1812	O

